secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioAge Labs, Inc. (BIOA)
CIK:        0001709941
Form:       8-K
Filed at:   2025-03-20T23:59:59+00:00
Accession:  0000950170-25-042747
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioAge Labs FY2024 net loss $71.1M; advances NLRP3 inhibitor BGE-102; discontinues azelaprag
--------------------------------------------------------------------------------

- Net loss of $71.1M ($6.63/share) for FY2024; cash $354.3M expected to fund operations through 2029.
- Discontinued azelaprag Phase 2 STRIDES trial due to unexpected liver transaminitis; continuing next-generation APJ agonists.
- Nominated BGE-102, an oral brain-penetrant NLRP3 inhibitor; Phase 1 SAD data expected 2H25, MAD data 1H26.
- New collaborations: Novartis (up to $20M upfront, $530M milestones) and Lilly (antibody discovery for metabolic aging targets).
- R&D expenses $59.0M (up 74% YoY); G&A $19.2M (up 32% YoY).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1709941/000095017025042747/0000950170-25-042747-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1709941/000095017025042747/bioa-20250320.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-042747

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer